Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23834492 | 1.00 | TNK2 (0.85) | TNK2 | |
| SCHEMBL23834477 | 1.00 | TNK2 (0.85) | TNK2 | |
| SCHEMBL4360606 | 0.92 | TNK2 (1.00) | TNK2 | |
| SCHEMBL1129353 | 0.92 | TNK2 (1.00) | TNK2 | |
| SCHEMBL23239695 | 0.89 | TNK2 (0.68) | TNK2 | |
| SCHEMBL1128909 | 0.89 | TNK2 (1.00) | TNK2 | |
| SCHEMBL1129183 | 0.87 | TNK2 (1.00) | TNK2 | |
| SCHEMBL4355745 | 0.87 | TNK2 (1.00) | TNK2 | |
| SCHEMBL4363600 | 0.85 | TNK2 (1.00) | TNK2 | |
| SCHEMBL4363604 | 0.85 | TNK2 (1.00) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4041401-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | HCK, LYN, BTK | TNK2 113/4885 |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | TNK2 1944/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | TNK2 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.